Elizabeth Fox, MD, MS
Elizabeth Fox, MD, MS

Elizabeth Fox, MD, MS

Member, St. Jude Faculty

  • Senior Vice President, Clinical Trials Research
  • Associate Director for Clinical Research, Comprehensive Cancer Center

Departments

Education

BS – Northeastern University, College of Pharmacy & Allied Health, Boston, Massachusetts
MD – Pennsylvania State University College of Medicine, Hershey, Pennsylvania
MS – Duke University College of Medicine, Durham, North Carolina
Internship – Strong Memorial Hospital, University of Rochester, Rochester, New York
Residency – Strong Memorial Hospital, University of Rochester, Rochester, New York
Fellowship – Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland

Military Service

Lieutenant Commander (LCDR/05), Department of Health & Human Services, US Public Health Service

Honors & Awards

  • 1991  Shapiro Scholar, Dept. Pediatrics, University of Rochester
  • 1995  Feigin Scholar, Texas Children's Hospital
  • 1999  NCI Fellowship Training Award
  • 2000  American Association for Cancer Research Glaxo Wellcome Oncology Scholar Award for Promising Clinical/Translational Research
  • 2002  American Society of Clinical Oncology Merit Award
  • 2006  NIH Director's Award of Merit for Contributions to Clinical Development of Treatment for Childhood Cancer (individual award)
  • 2008  NIH Award of Merit for the Transition of Carboxypeptidase Treatment Program (group award)

Research Interests

  • Developmental therapeutics in pediatric oncology

Selected Publications

Schafer ES,  Rau RE,  Berg SL,  Liu X, Minard CG, Bishop AJR Romero JC, Hicks MJ, Nelson Jr,  Voss S,  Reid JM, Fox E, Weigel BJ, Blaney SM. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: a Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatric Blood Cancer Feb;67(2):e28073, 2020.

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B,  Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M,  Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M,  Sigal D, Loong HH,  Buchschacher, Jr GL, Garrido P,  Jorge Nieva J, Steuer C, Overbeck TR,Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, n Eng S,  WilsonTR,  Demetri GD. Entrectinib in patients with advanced/metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1/2 trials. Lancet Oncology Feb;21(2):271-282, 2020.

Balis FM, Busch C, Desai AV,  Hibbitts E, Naranjo A, Bagatell R, Irwin M, Fox E. The Ganglioside, GD2, as a Circulating Tumor Biomarker for Neuroblastoma. Pediatric Blood Cancer Jan;67(1):e28031, 2020.

Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M,  Toporski J, Glade-Bender J,  Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. KEYNOTE-051: a phase 1/2 study of pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive advanced, relapsed, or refractory solid tumour or lymphoma. Lancet Oncology 2019 (in press).

Davis KL, Fox E, Reid JM, Kudgus RA,Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall C. A Phase I/II Trial of Nivolumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study, ADVL1412. Lancet Oncology 2019 (in press).

Poggesi I, Valenzuela B, Ouellet D, Gonzalez M, Hillewaert V, Baruchel S, Fox E, Perez-Ruixo JJ. Population pharmacokinetics of trabectedin in adolescent patients with cancer. Cancer Chemotherapy and Pharmacology Oct;84(4):707-717, 2019.

Mossé YP, Fox E, Teachey DT, Reid JM, Safgren SL, Carol H, Lock RB, Houghton PJ, Smith MA, Hall D, Barkauskas DA, Krailo M, Voss SD, Berg SL, Blaney SM, Weigel BJ. A Phase II Study of Alisertib in Children with Recurrent/RefractorySolid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clin Cancer Res Jun 1;25(11):3229-3238, 2019.

Busch CM, Desai AV, Moorthy GS, Fox E, Balis FM. A validated HPLC-MS/MS method for estimating the concentration of the ganglioside, G(D2), in human plasma or serum. J Chromatogr B Analyt Technol Biomed Life Sci Dec;1102-1103:60-65, 2018.

Geller JI, Fox E, Turpin BK, Goldstein SL, Liu X, Minard CG, Kudgus RA, Reid JM, Berg SL, Weigel BJ. A study of axitinib, a VEGF receptor tyrosine kinaseinhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer Nov;124(23):4548-4555, 2018.

Schafer ES, Rau RE, Berg S, Liu X, Minard CG, D'Adamo D, Scott R, Reyderman L, Martinez G, Devarajan S, Reid JM, Fox E, Weigel BJ, Blaney SM:.A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).  Pediatr Blood Cancer Aug;65(8), 2018.

Chuk MK, Widemann BC, Minard CG, Liu X, Kim A, Bernhardt MB, Kudgus RA, Reid JM, Voss SD, Blaney S, Fox E, Weigel BJ. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. Pediatric Blood and Cancer Aug;65(8):e27077, 2018. doi: 10.1002/pbc.27077

Fox E, Levin K, Zhu Y, Segers B, Balamuth N, Womer R, Bagatell R, Balis F. Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin. Oncologist Jul;23(7):762-79, 2018.

Chow EJ, Antal Z, Constine LS, Gardner R, Wallace WH, Weil BR, Yeh JM, Fox E. New agents, emerging late effects, and the development of precision survivorship. Journal of Clinical Oncology Jul;36(21):2231-2240, 2018.

Schafer ES, Rau RE, Berg S, Liu X, Minard CG, D'Adamo D, Scott R, Reyderman L, Martinez G, Devarajan S, Reid JM, Fox E, Weigel BJ, Blaney SM. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatric Blood and Cancer May;e27066, 2018. doi: 10.1002/pbc.27066

Kraft IL, Akshintala S, Zhu Y, Lei H, Derse-Anthony C, Dombi E, Steinberg SM, Lodish M, Wagerspack SG, Kapustina O, Fox E, Balis FM, Merino MJ, Meltzer PS, Glod JW, Shern JF, Widemann BC. Outcomes of children and adolescents with advanced hereditary medullary thyroid carcinoma treated with vandetanib. Clinical Cancer Research Feb;24(4):753-65, 2018.

Norris RE, Fox E, Reid JM, Ralya A, Lei XW, Minard C, Weigel BJ. Phase 1 trial of ontuximab (MORab-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatric Blood and Cancer May;65(5):e26944, 2018. doi: 10.1002/pbc.26944

London LB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR. Historical time-to-progression (TTP) and progression-free survival (PFS) in relapsed/refractory neuroblastoma modern-era (2002-14) patients from Children's Oncology Group (COG) early-phase trials. Cancer Dec;123(24):4914-4923, 2017.

Geller JI, Perentesis JP, Liu X, Minard CG, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ. Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ197) in Children with Relapsed or Refractory Solid Tumors (ADVL1111): A Children's Oncology Group Study Phase 1 and Pilot Consortium Trial. Ped Blood Cancer Nov;64(11), 2017. doi: 10.1002/pbc.26565

Balis FM, Womer RB, Berg S, Winick N, Adamson PC, Fox E. Dosing Anticancer Drugs in Infants: Current Approach and Recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force. Pediatric Blood and Cancer Nov;64(11), 2017. doi: 10.1002/pbc.26636

Mosse YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, Adamson PC, Blaney SB, Weigel BJ. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: A Children's Oncology Group Study. J Clin Oncol Oct;35(28):3215-3221, 2017.

Leary SES, Park JR, Reid JM, Ralya AT, Baruchel S, Wu B, Roberts TPL Liu X, Minard CG, Fox E, Weigel BJ, Blaney S. Pediatric phase 1 trial and pharmacokinetic study of trebananib in relapsed solid tumors ADVl1115: A Children's Oncology Group phase 1 consortium report. Clinical Cancer Research Oct;23(20):6062-6069, 2017.

Jain P,  Silva A, Han H, Lang SS, Zhu Y, Boucher K, Smith TE,  Vakil A,  Diviney P, Choudhari N, Raman P, Busch CM, Delaney T, Yang X, Olow AK,  Mueller S, Haas-Kogan D, Fox E, Storm PB, Resnick AC, Waanders AJ. Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. Oncotargets Sept;8(49):84697-84713, 2017.

Rheingold S, Tasian SJ, Whitlock JA, Teachey DT, Borowitz MJ, Liu X, Minard CG, Fox E, Weigel BJ, Blaney SM. A Phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia: a Children's Oncology Group study (ADVL1114). Br J Hematology May;177(3):467-474, 2017.

Balis FM, Thompson PA, Mosse YP, Blaney SB, Minard CG, Weigel BJ, Fox E. First Dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1 Consortium. Cancer Chemotherapy Pharmacology Jan;79(1):181-187, 2017.

Himebauch AS, SankarWN, Flynn JM, Sisko M, Moorthy G, Gerber JS, Zuppa AF, Fox E, Dormans JP, Kilbaugh TJ: Skeletal Muscle and Plasma Concentrations of Cefazolin during Complex Paediatric Spinal Surgery. Br J Anesthesia July;117(1):87-94, 2016.

DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.  J Clin Oncol Apr;34(12):1368-75, 2016.

Fox E, Widemann BC, Pastakia D Chen C, Yang S, Cole D, Balis F. Pharmacokinetic and Pharmacodynamic study of tariquidar (XR9576) a P-glycoprotien inhibitor, in combination with doxorubicin, vinorelbine or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemotherapy and Pharmacology Dec;76(6):1273-1283, 2015.

Kim A, Widemann BC, Krailo M, Jayaprakash N, Fox E, Weige BJ, Blaney SM. Phase 2 trial of Sorafenib in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group. Pediatric Blood and Cancer Sept;62(9):1562-1566, 2015.

Last update: March 2020

For updates on COVID-19, please read.